CD4 and neoplasm: The combination of 17-AAG and Tyrp1-specific CD4+ T cells treated mice showed significantly higher survival at Day 40 after tumor challenge when compared with Tyrp1-specific CD4+ T cells alone (P<0.05, Fig 8D).